Clinical trial
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight Related Comorbidity With or Without Type 2 Diabetes Mellitus (SELENE-Asia)
NCT07922330 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight Related Comorbidity With or Without Type 2 Diabetes Mellitus (SELENE-Asia)
- Lead sponsor
- AstraZeneca
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- January 4, 2027
- Completion date
- September 15, 2028
- Enrollment
- 330 (estimated)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.
obesity, overweight, type 2 diabetes mellitus
Lead sponsor's other trials
AstraZeneca, most recent start first.
+3,493 more trials See the organization page
Similar trials
Same condition (Diabetes Mellitus, Type 2) and phase, most recent start first.
+1,316 more trials See the condition page